Yanan Zhu
Stock Analyst at Wells Fargo
(1.96)
# 3,628
Out of 5,182 analysts
85
Total ratings
38.36%
Success rate
-7.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Overweight | $50 → $90 | $68.63 | +31.14% | 4 | Apr 14, 2026 | |
| CYTK Cytokinetics | Initiates: Overweight | $95 | $60.69 | +56.53% | 1 | Apr 10, 2026 | |
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $18.05 | +232.41% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $13.20 | +13.64% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $21.07 | +80.35% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $115.07 | -0.06% | 1 | Feb 23, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $6.30 | +74.60% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $71.78 | +39.31% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $8.87 | +125.48% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $3.06 | +30.72% | 7 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $28.72 | +56.69% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.44 | +733.33% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.30 | +92.31% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.48 | +237.84% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $3.38 | +314.20% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $30.56 | +129.06% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.77 | +165.25% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $52.06 | +24.86% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.96 | +331.03% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.20 | +1,890.05% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.59 | +17,274.52% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $775.03 | -57.94% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.24 | +583.59% | 2 | Oct 29, 2020 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $90
Current: $68.63
Upside: +31.14%
Cytokinetics
Apr 10, 2026
Initiates: Overweight
Price Target: $95
Current: $60.69
Upside: +56.53%
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $18.05
Upside: +232.41%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.20
Upside: +13.64%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $21.07
Upside: +80.35%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $115.07
Upside: -0.06%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $6.30
Upside: +74.60%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $71.78
Upside: +39.31%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $8.87
Upside: +125.48%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $3.06
Upside: +30.72%
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $28.72
Upside: +56.69%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.44
Upside: +733.33%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.30
Upside: +92.31%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.48
Upside: +237.84%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $3.38
Upside: +314.20%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $30.56
Upside: +129.06%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.77
Upside: +165.25%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $52.06
Upside: +24.86%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $6.96
Upside: +331.03%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.20
Upside: +1,890.05%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.59
Upside: +17,274.52%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $775.03
Upside: -57.94%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.24
Upside: +583.59%